1. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease: impact of new treatment options. Pharmacoeconomics 2001; 19(3): 245–54
2. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278–85
3. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive Summary. Respir Care 2001 Aug; 46(8): 798–825
4. Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 2001 Jul; 120(1): 258–70
5. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77–120